IMMUNOPHARMA AS

0283 OSLO

Finances

Return on Equity

−29,2 %

Current Ratio

2,15

Debt-to-Equity Ratio

0,34

Key figures (NOK)	2022	2021	2020	2019
Revenue	482 068 000	390 860 000	316 584 000	2 337 000
Net Income	−59 688 000	−26 008 000	−25 619 000	−292 000
Total Assets	381 162 000	351 239 000	391 175 000	434 084 000
Total Equity	204 442 000	243 941 000	138 023 000	322 550 000

Income (NOK)	2022	2021	2020	2019
Revenue	482 068 000	390 860 000	316 584 000	2 337 000
Expenditure	533 301 000	440 145 000	351 120 000	13 443 000
Operating Profit	−51 233 000	−49 285 000	−34 536 000	−11 106 000
Financial Income	11 235 000	35 988 000	26 747 000	827 000
Financial Costs	9 723 000	9 970 000	11 777 000	4 000
Financial Balance	1 512 000	26 018 000	14 970 000	823 000
Earnings Before Tax	−49 721 000	−23 267 000	−19 566 000	−10 283 000
Tax	9 967 000	2 741 000	6 054 000	−9 991 000
Net Income	−59 688 000	−26 008 000	−25 619 000	−292 000

Balance (NOK)	2022	2021	2020	2019
Total Fixed Assets	151 250 000	219 267 000	287 173 000	334 341 000
Total Current Assets	229 912 000	131 972 000	104 002 000	99 743 000
Total Assets	381 162 000	351 239 000	391 175 000	434 084 000
Total Retained Equity	−110 331 000	−80 913 000	−29 462 000	13 342 000
Total Equity	204 442 000	243 941 000	138 023 000	322 550 000
Total Long-Term Debt	69 831 000	32 835 000	181 187 000	189 838 000
Total Current Debt	106 889 000	74 463 000	71 964 000	82 970 000
Total Equity and Debt	381 162 000	351 239 000	391 175 000	434 084 000

Cash flow (NOK)	2022	2021	2020	2019
Sales Income	482 039 000	390 769 000	316 584 000	2 337 000
Other Income	29 000	91 000	0	0
Revenue	482 068 000	390 860 000	316 584 000	2 337 000
Cost of Goods Sold	134 716 000	108 784 000	83 249 000	1 259 000
Salary Costs	52 143 000	38 793 000	29 383 000	1 036 000
Depreciation	1 404 000	1 244 000	63 733 000	0
Impairment	64 163 000	64 140 000	0	0
Expenditure	533 301 000	440 145 000	351 120 000	13 443 000
Operating Profit	−51 233 000	−49 285 000	−34 536 000	−11 106 000
Financial Income	11 235 000	35 988 000	26 747 000	827 000
Financial Costs	9 723 000	9 970 000	11 777 000	4 000
Financial Balance	1 512 000	26 018 000	14 970 000	823 000
Dividends	0	0	0	0
Net Income	−59 688 000	−26 008 000	−25 619 000	−292 000

Balance details (NOK)	2022	2021	2020	2019
Goodwill	130 117 000	194 280 000	260 967 000	312 021 000
Total Intangible Assets	140 198 000	207 212 000	273 812 000	327 363 000
Real Eastate	4 902 000	5 445 000	5 979 000	6 881 000
Machinery and Plant Facilities	0	0	0	0
Fixtures	350 000	354 000	0	0
Total Tangible Assets	5 252 000	5 799 000	5 979 000	6 881 000
Total Fiancial Fixed Assets	5 800 000	6 256 000	7 381 000	97 000
Total Fixed Assets	151 250 000	219 267 000	287 173 000	334 341 000
Stock	27 472 000	23 719 000	10 958 000	15 142 000
Total Investments	0	0	32 045 000	13 479 000
Cash, Bank	105 363 000	76 794 000	41 310 000	20 062 000
Total Current Assets	229 912 000	131 972 000	104 002 000	99 743 000
Total Assets	381 162 000	351 239 000	391 175 000	434 084 000
Total Equity	204 442 000	243 941 000	138 023 000	322 550 000
Short-Term Group Debt	0	0	0	0
Total Long-Term Debt	69 831 000	32 835 000	181 187 000	189 838 000
Creditors	31 211 000	19 095 000	13 248 000	17 103 000
Unpaid Taxes	9 112 000	4 459 000	8 524 000	3 928 000
Dividends	0	0	0	0
Other Current Debt	58 847 000	50 609 000	42 281 000	50 516 000
Total Current Debt	106 889 000	74 463 000	71 964 000	82 970 000
Total Equity and Debt	381 162 000	351 239 000	391 175 000	434 084 000

Financial indicators	2022	2021	2020	2019
Return on Equity	−29,2 %	−10,66 %	−18,56 %	−0,09 %
Debt-to-Equity Ratio	0,34	0,13	1,31	0,59
Operating Profit Margin	−10,63 %	−12,61 %	−10,91 %	−475,22 %
Current Ratio	2,15	1,77	1,45	1,2
Quick Ratio	2,89	2,6	1,7	1,47
Equity Ratio	0,54	0,69	0,35	0,74
Gross Profit Margin	72,05 %	72,17 %	73,7 %	46,13 %